EcoDrugPlus

Tyrosinase

Ensembl ID : ENSCMIG00000013755
Gene Symbol: TYR
4 Cross references
266 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSCMIG00000008362
Gene Symbol: TH
3 Cross references
188 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSCMIG00000016465
Gene Symbol: TYK2
3 Cross references
197 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSCMIG00000004195
Gene Symbol: TIE1
3 Cross references
207 Possible Orthologues:

Tyrosine-Protein Kinase Receptor Ufo-Like

Ensembl ID : ENSCMIG00000004782
Gene Symbol: LOC103173140
3 Cross references
199 Possible Orthologues:

Utrophin

Ensembl ID : ENSCMIG00000007999
Gene Symbol: UTRN
3 Cross references
269 Possible Orthologues:

Vascular Endothelial Growth Factor A

Ensembl ID : ENSCMIG00000005000
Gene Symbol: VEGFA
4 Cross references
253 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSCMIG00000012222
Gene Symbol: VDR
4 Cross references
467 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1c-Like

Ensembl ID : ENSCMIG00000014856
Gene Symbol: LOC103179419
3 Cross references
215 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1s-Like

Ensembl ID : ENSCMIG00000002486
Gene Symbol: LOC103172036
2 Cross references
196 Possible Orthologues:

Voltage-Dependent P/q-Type Calcium Channel Subunit Alpha-1a-Like

Ensembl ID : ENSCMIG00000004073
Gene Symbol: LOC103172859
2 Cross references
194 Possible Orthologues:

Voltage-Dependent T-Type Calcium Channel Subunit Alpha-1h-Like

Ensembl ID : ENSCMIG00000014040
Gene Symbol: LOC103190512
2 Cross references
210 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).